Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 264Neoplasms 145Breast Neoplasms 137Colorectal Neoplasms 126Neoplasm Metastasis 94Prostatic Neoplasms 92Ovarian Neoplasms 91Multiple Myeloma 90Lung Neoplasms 86Squamous Cell Carcinoma of Head and Neck 62Pancreatic Neoplasms 61Recurrence 55Endometrial Neoplasms 55Small Cell Lung Carcinoma 50Melanoma 50Stomach Neoplasms 49Leukemia, Lymphocytic, Chronic, B-Cell 48Leukemia, Myeloid, Acute 45Carcinoma, Renal Cell 45Lymphoma, Non-Hodgkin 40Advanced Solid Tumors 39Triple Negative Breast Neoplasms 38Urinary Bladder Neoplasms 37Parkinson Disease 4, Autosomal Dominant Lewy Body 35Head and Neck Neoplasms 35Carcinoma, Hepatocellular 35Lymphoma, Large B-Cell, Diffuse 33Esophageal Neoplasms 31Lymphoma, Follicular 29Myasthenia Gravis 28

Interventions

luspatercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × beta-Thalassemia × 30 days × Clear all
NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡